{"entity":{"id":"nct06795022","kind":"trial","name":"First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours","aka":["RHEA-1"],"tldr":"A phase 1/2 trial of AZD9793 in hepatocellular carcinoma, run by AstraZeneca, now recruiting.","summary":"First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours is a phase 1/2 interventional study registered as NCT06795022 by AstraZeneca, with 304 participants planned, started 2025-03-27 and due to reach its primary completion in 2027-06-30. Interventions recorded: AZD9793 Intravenous (IV) monotherapy and AZD9793 Subcutaneous (SC) monotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06795022","url":"https://clinicaltrials.gov/study/NCT06795022"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["azd9793"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06795022","phase":"1/2","setting":"A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)","sponsor":"AstraZeneca","participation":[{"nct":"NCT06795022","source":"https://clinicaltrials.gov/study/NCT06795022","fetchedAt":"2026-10-07T16:55:03.017Z","studySha256":"d94e847063551d40eeebd86cd3efd6b5d3b37d75bd49a4f205268bd0f7a67ecd","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-13","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":304,"enrolmentType":"ESTIMATED","siteCount":21,"recruitingSiteCount":13,"countries":["China","Hong Kong","Japan","South Korea","Spain","Taiwan","United States"]}],"started":"2025-03-27","startedType":"actual","enrolled":304,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06795022/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"azd9793","kind":"drug","name":"AZD9793","route":"/drugs/azd9793/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}